ID
45866
Description
Principal Investigator: Richard Wilson, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001005 This study of three metastatic melanoma patients utilized exome sequencing and RNA sequencing to help identify putative neoantigen peptides that could be further validated by standard immunological assays before design of a personalized vaccine. For each set of neoantigens identified and verified by standard assays, we designed GMP peptides that correspond to the top neoantigens, then used these to condition dendritic cell isolates from each patient. The conditioned dendritic cells were used as the vaccine in three rounds of vaccination, followed by monitoring for T cell memory response to each of the neoantigens.
Link
Keywords
Versions (1)
- 10/14/23 10/14/23 - Simon Heim
Copyright Holder
Richard Wilson, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA
Uploaded on
October 14, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs001005 Antigen Discovery in Melanoma
Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID and gender of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Sample ID, histological type, analyte type, body site where sample was obtained, tumor status of sample, and year when sample was collected from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
Similar models
Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID and gender of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Sample ID, histological type, analyte type, body site where sample was obtained, tumor status of sample, and year when sample was collected from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
C2348585 (UMLS CUI [1,2])